Thyroid and hepatic function after high‐dose 131I‐metaiodobenzylguanidine (131I‐MIBG) therapy for neuroblastoma (Q34424834)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article published on September 9, 2010

Language	Label	Description	Also known as
English	Thyroid and hepatic function after high‐dose 131I‐metaiodobenzylguanidine (131I‐MIBG) therapy for neuroblastoma	scientific article published on September 9, 2010

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Thyroid and hepatic function after high‐dose 131I‐metaiodobenzylguanidine (131I‐MIBG) therapy for neuroblastoma (English)

1 reference

10.1002/PBC.22767

https://api.crossref.org/works/10.1002/PBC.22767

10 July 2024

Katherine K Matthay

16

object named as

Katherine K Matthay

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

12

object named as

John M Maris

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Benjamin L Franc

7

object named as

Benjamin Franc

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20830775

10 July 2024

author name string

Alekist Quach

1

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Lingyun Ji

2

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Vikash Mishra

3

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Aimee Sznewajs

4

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Janet Veatch

5

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

John Huberty

6

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Richard Sposto

8

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Susan Groshen

9

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Denice Wei

10

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Paul Fitzgerald

11

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Gregory Yanik

13

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Randall A. Hawkins

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20830775

10 July 2024

Judith G. Villablanca

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20830775

10 July 2024

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20830775

10 July 2024

publication date

9 September 2010

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

full work available at URL

http://deepblue.lib.umich.edu/bitstream/2027.42/78497/1/22767_ftp.pdf

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20830775

10 July 2024

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20830775/?tool=EBI

online access status

content deliverer

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20830775

10 July 2024

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20830775/pdf/?tool=EBI

online access status

content deliverer

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20830775

10 July 2024

https://europepmc.org/articles/PMC3006009

online access status

content deliverer

Europe PubMed Central

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20830775

10 July 2024

https://europepmc.org/articles/PMC3006009?pdf=render

online access status

content deliverer

Europe PubMed Central

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20830775

10 July 2024

https://doi.org/10.1002/pbc.22767

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20830775

10 July 2024

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fpbc.22767

1 reference

10.1002/PBC.22767

https://api.crossref.org/works/10.1002/PBC.22767

10 July 2024

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.22767

1 reference

10.1002/PBC.22767

https://api.crossref.org/works/10.1002/PBC.22767

10 July 2024

Pediatric Blood & Cancer

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

56

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

191-201

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Mechanisms behind the non-thyroidal illness syndrome: an update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3006009

6 July 2018

Thyroid cancer after external or internal ionizing irradiation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3006009

6 July 2018

Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3006009

6 July 2018

Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3006009

6 July 2018

Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3006009

6 July 2018

Cumulative incidence in competing risks data and competing risks regression analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3006009

6 July 2018

A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3006009

6 July 2018

Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3006009

6 July 2018

Secondary myelodysplastic syndrome and leukemia following 131I-metaiodobenzylguanidine therapy for relapsed neuroblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3006009

6 July 2018

Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3006009

6 July 2018

Thyroidal uptake and radiation dose after repetitive I-131-MIBG treatments: influence of potassium iodide for thyroid blocking

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3006009

6 July 2018

Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3006009

6 July 2018

131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3006009

6 July 2018

Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3006009

6 July 2018

131I-MIBG as a first-line treatment in high-risk neuroblastoma patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3006009

6 July 2018

Results of treatment with 131 I-metaiodobenzylguanidine (131 I-MIBG) in patients with neuroblastoma. Future prospects of zetotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3006009

6 July 2018

Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Study Group investigation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3006009

6 July 2018

Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.

1 reference

https://api.crossref.org/works/10.1002%2FPBC.22767

21 January 2018

Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study.

1 reference

https://api.crossref.org/works/10.1002%2FPBC.22767

21 January 2018

Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma

1 reference

https://api.crossref.org/works/10.1002%2FPBC.22767

21 January 2018

Endocrine late effects from multi-modality treatment of neuroblastoma

1 reference

https://api.crossref.org/works/10.1002%2FPBC.22767

21 January 2018

Improved radiation protection of the thyroid gland with thyroxine, methimazole, and potassium iodide during diagnostic and therapeutic use of radiolabeled metaiodobenzylguanidine in children with neuroblastoma

1 reference

https://api.crossref.org/works/10.1002%2FPBC.22767

21 January 2018

High incidence of thyroid dysfunction despite prophylaxis with potassium iodide during (131)I-meta-iodobenzylguanidine treatment in children with neuroblastoma

1 reference

https://api.crossref.org/works/10.1002%2FPBC.22767

21 January 2018

Transient sialoadenitis: a complication of 131I-metaiodobenzylguanidine therapy

1 reference

https://api.crossref.org/works/10.1002%2FPBC.22767

21 January 2018

Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine

1 reference

https://api.crossref.org/works/10.1002%2FPBC.22767

21 January 2018

Thyroid neoplasms after therapeutic radiation for malignancies during childhood or adolescence

1 reference

https://api.crossref.org/works/10.1002%2FPBC.22767

21 January 2018

Hepatic absorbed radiation dosimetry during I-131 metaiodobenzylguanidine (MIBG) therapy for refractory neuroblastoma

1 reference

https://api.crossref.org/works/10.1002%2FPBC.22767

21 January 2018

Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3006009

27 October 2018

Long-term results of [131I]metaiodobenzylguanidine treatment of refractory advanced neuroblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3006009

27 October 2018

Primary hypothyroidism as a consequence of 131-I-metaiodobenzylguanidine treatment for children with neuroblastoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20830775

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radiochemical purity, at expiry, and radiochemical stability of iodine-131 labelled meta-iodobenzylguanidine concentrates for intravenous infusion

1 reference

https://pubmed.ncbi.nlm.nih.gov/20830775

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of neuroblastoma stage 4 with 131I-meta-iodo-benzylguanidine, high-dose chemotherapy and immunotherapy. A pilot study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20830775

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of neuroblastoma with [131I]metaiodobenzylguanidine: long-term results in 25 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/20830775

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic use of [131I]metaiodobenzylguanidine in neuroblastoma: a phase II study in 26 patients. "Société Française d'Oncologie Pédiatrique" and Nuclear Medicine Co-investigators

1 reference

https://pubmed.ncbi.nlm.nih.gov/20830775

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The normal and abnormal distribution of the adrenomedullary imaging agent m-[I-131]iodobenzylguanidine (I-131 MIBG) in man: evaluation by scintigraphy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20830775

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/PBC.22767

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34424834&oldid=2200284227"